LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
Recruiting · NCT06778512 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t
What this trial is about
This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Signing of the informed consent form;
- Male or female, aged 18-75 years;
- Patients with lung nodules confirmed by CT examination;
- Good preoperative pulmonary function cooperation and complete reporting;
- Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
- The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.
Exclusion criteria
- Poor preoperative pulmonary function cooperation or missing reports;
- Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
- The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
- Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
- Coexisting with other severe functional impairments;
- Patients with obstructive lesions such as airway or esophageal stenosis;
- Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Where it is running
1 location listed.
- the First Affiliated of Guangzhou Medical University - Guangzhou, Guangdong, China